網膜缺血或實驗性青光眼：黃芩內含成分黃芩素之神經保護及機轉探討

趙效明
臺北榮民總醫院
本研究所採用高眼壓網膜缺血模式（high intraocular pressure-induced retinal ischaemia）60分鐘，提供可重複性之網膜缺血，可檢測葯劑對「網膜缺血」或「實驗性青光眼」之療效。本模式雖和慢性青光眼有所不同，然而眼壓高於一定程度時將造成眼內血流減少及視神經盤之機械性壓迫（Hughes，1991），因而此模式至少可供探討青光眼的尚未瞭解之致病機轉（如和氫氧根游離基、基質金屬蛋白酶第九型訊息核糖核酸、神經滋養因子之關係）。
「網膜缺血」或「實驗性青光眼」模式之建立﹔研究擬神經保護劑黃芩素﹙黃芩內含成分﹚，對疾病模式的療效﹔藥物療效之保護機轉為何？1. 釋放特定因子，保護變性的網膜細胞或延緩其死亡？2. 抵消毒性﹙氫氧根游離基、基質金屬蛋白酶﹚？
關鍵字：網膜缺血、實驗性青光眼、黃芩素

Therapeutic effects/mechanisms of baicalein against retinal ischaemia or experimental glaucoma

Hsiao-Ming Chao
Taipei Veterans General Hospital
An increase in intraocular pressure (IOP) to a certain level (e.g. beyond systolic blood pressure) can result in a reduction in ocular blood flow and mechanical compression in the optic nerve head region. An experimental glaucoma animal model is designed utilizing the anterior chamber cannulation to create a high intraocular pressure (HIOP) for 60 minutes. The HIOP procedure provides a reproducible and appropriate degree of retinal ischaemic changes (hypoxia/anoxia) and is considered as a satisfactory way to evaluate how defined agents affect retinal ischaemia/ reperfusion or experimental glaucoma. An investigation will be made into the underlying mechanism of glaucoma [e.g. its relationship with the expression of hydroxyl redicals, glia-derived neurotrophic factor (GDNF), and matrix metalloproteinase (MMP)].
Whether baicalein would provide protective effects and their possible protective mechanis will also be evaluated.
關鍵字：retinal ischaemia, experimental glaucoma, baicalein